Halving the price of artificial organs and bionic prostheses
What is Hélice ?
The Hélice company aims at drastically reducing the price of bionic prostheses and artificial organs such as retinal or neural implants, heart prosthesis, exoskeletons etc,.
These technologies are very expensive (≈ 100 000€).
Unfortunately, this sector is developing very slowly.
Indeed, among other particular factors, these are very customized, which is why there is no large-scale production possible.
Hélice has therefore designed innovative financial engineering based on blockchain technology to divide the price of prostheses -up to 50% -without any changes being made to the prosthesis !
Why acquire $Hélice ?
Thanks to the token many patients will access to highly sophisticated prostheses capable of greatly improving their lives or even saving them. Thanks to this beneficial impact on society, the Hélice token can acquire a great visibility.
Moreover, if you own tokens then this gives you priority access to discounted prostheses.
$Hélice is unique. Our ERC-20 token has a maximum supply of 1 unit.
You will never see your savings diluted by new tokens created by an unscrupulous team!
The owner of the Hélice token can earn 1.1% transaction fees. Indeed, transaction fees are the main source of revenue for almost all exchanges, but since we make money selling prostheses, a part of these fees will be given to users !
Hélice is a real company. Its products, and its patients, are real.
Our competitive advantage is that we can sell prostheses at lower prices than our competitors without making any modification to the prosthesis.
This market will exceed $53 billion by 2027 and demand will increase as the technology improves.
One day, we hope to be able to distribute a dividend (when regulations allow).
Liquidity is continuously fed back into the model. Indeed, after a patient purchases the prosthesis (Figure 2), Hélice realizes a buyback. This liquidity comes from a real creation of value and puts buying pressure on the token.
Then, Hélice performs a burn of its own token, thus progressively reducing the total supply overtime and making the Hélice token even more scarce...
Hélice is part of a “disruptive” approach to the sector, first by radically reducing prices for as many patients as possible to benefit from them, and then, by using the capital to invest substantially in order to improve these technologies.
Without Hélice intervention, such a process would normally be extremely slow given the particular factors of our sector as mentioned above. But thanks to Hélice, this process will be strongly speeded up and 2030 will be the new 2050 !
*This does not represent a financial entitlement. Hélice can reduce or eliminate the amount allocated at its own discretion.
Why acquire $Hélice ?
Thanks to the token many patients will access to highly sophisticated prostheses capable of greatly improving their lives or even saving them. Thanks to this beneficial impact on society, the Hélice token can acquire a great visibility.
Moreover, if you own tokens then this gives you priority access to discounted prostheses.
$Hélice is unique. Our ERC-20 token has a maximum supply of 1 unit.
You will never see your savings diluted by new tokens created by an unscrupulous team!
Owner of $Hélice can earn 1.1% transaction fees. Indeed, transaction fees are the main source of revenue for almost all exchanges, but since we make money selling prostheses, a part of these fees will be given to users !
Hélice is a real company. Its products, and its patients, are real.
Our competitive advantage is that we can sell prostheses at lower prices than our competitors without making any modification to the prosthesis.
This market will exceed $53 billion by 2027 and demand will increase as the technology improves.
One day, we hope to be able to distribute a dividend (when regulations allow).
Liquidity is continuously fed back into the model. Indeed, after a patient purchases the prosthesis (Figure 2), Hélice realizes a buyback. This liquidity comes from a real creation of value and puts buying pressure on the token.
Then, Hélice performs a burn of its own token, thus progressively reducing the total supply overtime and making the Hélice token even more scarce...
Hélice is part of a “disruptive” approach to the sector, first by radically reducing prices for as many patients as possible to benefit from them, and then, by using the capital to invest substantially in order to improve these technologies.
Without Hélice intervention, such a process would normally be extremely slow given the particular factors of our sector as mentioned above. But thanks to Hélice, this process will be strongly speeded up and 2030 will be the new 2050 !
*This does not represent a financial entitlement. Hélice can reduce or eliminate the amount allocated at its own discretion.
A first patient in 2021
Dylan was the first person to take advantage of the Hélice program, in an amount of 107,000€. This program allowed him to acquire the most sophisticated knee prosthesis in the world (Genium x3).
Roadmap
Creation of the Hélice Model
First use case with Dylan
Presentation to the community
Presale & Partnerships
Token available on a Cex or/and on the Hélice platform.
First halving of our
partners' price and first buyback-burn.
Continuation of the
process until the Hélice token reaches a price/market cap of $100M.
More than 100 patients fitted with the most advanced prostheses
First milestone (not disclosed at this stage)
Creation of an R&D laboratory
Our Advisors (in progress...)
Bernard Verrier | Ph.D in Molecular Virology
Born in France in 1957 and trained as a chemist, before getting a phD in molecular virology in 1985 and post-doctorated for three years at the EMBL, Germany, in retroviral oncology. Then, he moved to Lyon (France) to study human retrovirology, designing HIV vaccine candidates, either therapeutic, using tat,rev or nef regulatory proteins or prophylactic, with gp140 constructs, through a permanent position at CNRS. Director of research from CNRS since 2004, he was head of a joint unit between CNRS and bioMerieux, dedicated to HIV and HCV therapeutic vaccines, before beeing head of the department « Tissue biology and therapeutic engineering » at IBCP (www.ibcp.fr), in 2010, a joint unit between CNRS and University of Lyon. His research group is elaborating biodegradable particulate vaccines for human infectious diseases (HIV, HSV, Flu & HBV) using innate immunity ligands as adjuvants or therapeutic tools, and colloidal vectors for delivery of either proteins or nucleic acids, with a strong emphasis on tracking in animal models the journey of such vaccine vehicles. This expertise allows him to coordinate and to participate to various national and European research programs involving particulate vaccines and adjuvants, such as Cuthivac (www.cuthivac.eu), iNanoDCs (www.euronanomed.net) or Aditec (www.aditecproject.eu) programs.
anton sindali | surgeon
(Bio in process)
Denis Chriqui | Ph.D in economics
Economist and former professional trader. After a Ph.D in economics from the University of Montpellier and training at the Wharton School, Denis was for more than 16 years a business buyer, professor of economics, specialist and researcher in behavioral finance, trainer in technical analysis and director of an import-export company. He worked as a professional trader in New York at Herzog Heine Geduld (Merrill Lynch) and E Trade for more than 6 years as an arbitrageur-strategist on derivatives, then in portfolio management and front office manager. Since 2004, Denis has been devoting himself to his vocation for teaching and proprietary trading.
Thierry Monmasson | Ph.D in Pharmaceutical Sciences
1986: Scientific Baccalaureate (French diploma of secondary education), Cannes.
1993: Pharmacist Diploma: six-year university degree in industrial pharmacy with honors at the University of Pharmacy of Marseille.
1998: Master degree in Sciences, speciality Biochemistry and genetics at the University of medecine of Marseille.
1999: Diplôme d’études approfondies: one-year degree before postgraduate studies in cellular and molecular biology at the University of medecine of Marseille.
RESEARCH :
Study of chaperone proteins and thyroid hormonegenesis, contribution to the study of the action of the disulfide isomerase protein in the thyroglobulin metabolism.
Work experience :
1992 – 1993: Product chemist intern, Rousset, France.
1998 – 1999: Intern within the Laboratory of proteins engineering at the university of Marseille, France.
1995 – 2013: Pharmacist practicing in pharmacies.
Since 2012: Teacher in Biophysics.
olivier Rousselle | Ph.D in Quantum Physics
Passionate by science and by the universe, Olivier has obtained a PhD in quantum physics at Sorbonne Université in 2022. He has dealt with different research topics until now: particle physics and software development at CERN; foundations of quantum physics at ENS; modeling and statistics at CNRS; biology and environmental studies at AgroParisTech.
Moreover, he is passionate about the crypto / blockchain ecosystem, and he is currently involved in the development of efficient crypto algorithmic bots.
Curriculum : PhD in Physics at Sorbonne Université (2019-2022).
Master in Theoretical Physics at Aix-Marseille Université (2018-2019).
Engineer School AgroParisTech (2013-2017).
Florian Ravaz | Ph.D in law
2007-2010 : Law degree (University of Toulon)
2010-2011 : Master of Law, Mention public law and private law (University of Toulon)
2011-2012 : Master of Notarial Law (University of Toulon).
2012-2016 : PhD in public law on "Taxation of non -resident foreigners in France", very honorable mention (University of Toulon).
Samuel G. Ongala-Eedoumou I MSc In physics
Doctoral studies: Radiative Properties of magnetic fusion plasmas: from density matrix to plasma atom - Sorbonne Université
2016 - 2019 (Not completed)
Master’s Degree - Magnetic Fusion
Confinement
Université Pierre et Marie Curie (Paris VI)
2012 - 2015
Diploma in Basic Physics
International Center for Theoretical Physics
Trieste, Italy
2011 - 2012
Maitrise de Physique
Université Marien Ngouabi
Congo
2009 - 2010
Licence de Physique
Université Marien Ngouabi
Congo
2008 - 2009
Adrien Marchand | MSc in international Finance
ESM IAE Metz Master 2, International Finance · (2017 - 2018).
Санкт-Петербургский Государственный Университет Экономики
и Финансов
Master 1 Management International · (2016 - 2017)
Université d'Angers
Licence Sciences Economiques et de Gestion, International
management · (2015 - 2016).
PARTNERS (In progress...)
HÉLICE PROSTHESIS
9A Boulevard de Strasbourg 83000 Toulon, France (New).
Maximum supply of 1 Unit